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ABSTRACT
CREATION OF NOVEL INDUCIBLE CELL LINE TO STUDY ALVEOLAR
RHABDOMYOSARCOMA. Kaoru Takasaki, Ranjini K. Sundaram, Ranjit S. Bindra.
Departments of Therapeutic Radiology and of Pathology, Yale University, School of
Medicine, New Haven, CT.
Rhabdomyosarcoma (RMS) is a group of relatively rare mesenchymal malignancies
classically associated with skeletal muscle and most frequently seen in the pediatric
population. While chemotherapy, radiation, and surgical resection can confer long-term
event-free survival rates of up to 85-95%, the prognosis for alveolar rhabdomyosarcoma
(ARMS), particularly those positive for either the t(2;13) PAX3-FOXO1 or t(1;13) PAX7FOXO1 translocation, is significantly worse. As such, the development of therapies that are
specific for fusion-positive ARMS cells are of particular clinical interest, and it has been
suggested that the concept of synthetic lethality can be exploited to target genes that become
essential for cellular survival only in the presence of PAX3/7-FOXO1 expression. A stable
tetracycline-inducible PAX3-FOXO1 clonal cell line in a U2OS background is created here
in order to study in isolation the effects of the fusion protein on tumor response to novel
chemotherapeutic agents. The cell line’s validity as a genetic mimic of PAX3-FOXO1
positive ARMS is verified by testing via qPCR the upregulation of DAPK, FGFR4, GREM1,
and MyoD, which serve as proxies for global gene expression changes in fusion-positive
ARMS, in the induced vs. uninduced states. DAPK and MyoD consistently demonstrate a
statistically significant upregulation, as expected, but data for FGFR4 and GREM1 are
inconclusive. Although additional experiments therefore need to be conducted to fully
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confirm that the inducible cell line indeed exhibits the transcriptional reprogramming seen in
PAX3/7-FOXO1 positive ARMS, the data so far support this hypothesis. Ultimately, this cell
line will be used in a high-throughput assay to identify chemotherapeutic agents that
preferentially kill those with PAX3-FOXO1 expression, with the hopes of improving the
poor prognosis that fusion-positive ARMS patients currently face.

3

ACKNOWLEDGEMENTS
I would first like to express my sincere gratitude to my PI and thesis advisor,
Professor Ranjit Bindra, for providing constant motivation, insight, and support for my
research. His understanding of the demands of medical school was pivotal in ensuring the
progress of my research. I must also thank Ranjini Sundaram, Ph.D., who often maintained
cell cultures and carried out parts of my project in my absence, and the other members of the
Bindra Lab who offered advice and encouragement throughout. The Barr Lab (National
Cancer Institute), Jensen Lab (Yale School of Medicine), and Glazer Lab (Yale School of
Medicine) generously provided materials and expertise that greatly assisted my research.
I am also immensely grateful to Professor Benjamin Gewurz (Harvard Medical
School) for introducing me to the joys and rigors of strong scientific research, and for
patiently teaching me all of my foundational bench skills.
This research was supported by the Alex’s Lemonade Stand Foundation Pediatric
Oncology Student Training (POST) Program Grant (2013), the Yale First Year Summer
Student Fellowship (2013), and the Cure Search Young Investigator-2 Grant (awarded to
Professor Bindra, 2015-2018).

4

TABLE OF CONTENTS
I. Introduction .......……………………………………………………………….…... page 6

II. Statement of Purpose .…………………………………………………………….. page 19

III. Methods .………………………………………………………………….…….… page 20

IV. Results ...………………………………………………………………….…….… page 29

V. Discussion ..…………………………………………………………………….… page 41

VI. References ..…………………………………………………………………….… page 45

VII. Supplementary Materials ..……………………………………………………...… Online

5

I. INTRODUCTION
Rhabdomyosarcoma (RMS) is a group of mesenchymal malignancies classically
associated with skeletal muscle but also frequently found in other parts of the body such as
the head, neck, biliary tract, and urogenital tract. While they are the most common soft-tissue
tumors and the third most common extracranial solid tumors in the pediatric population, they
are still relatively rare overall, with incidence rates of 0.5-0.6 per 100,000 in patients 0-14
years of age (1) and an estimated 350 new cases in the United States each year (2). Among
the various subtypes of RMS, alveolar rhabdomyosarcoma (ARMS) is distinct in its
epidemiology, prognosis, and genetic signature. It is typically found in older children and
teenagers, although two-thirds of RMS patients overall are diagnosed before their sixth
birthday (3), and patients more often present with metastatic disease at the time of diagnosis
compared to other subtypes (4). The latter tendency is at least in part explained by the fact
that RMS begins as an asymptomatic mass, with or without accompanying mass effects, and
such masses in adolescents are often attributed to a musculoskeletal injury (3). This delay in
presentation and diagnosis carries unfavorable implications for prognosis; ARMS patients are
automatically stratified into at least the intermediate risk category, and while treatment with
chemotherapy, radiation, and/or surgery currently allows 60-70% of ARMS patients with
localized disease to survive long-term, the long-term event-free survival rate for those with
metastatic disease is as low as 15%. In contrast, patients with the more favorable embryonal
rhabdomyosarcoma (ERMS) see long-term event-free survival rates of up to 85-95% if
localized or completely resected, and approximately 35% if metastatic (5). Early diagnosis
and effective treatment of ARMS therefore remains a clinical challenge.
ARMS cases can be further be subclassified into fusion-positive and fusion-negative;

6

50-80% of ARMS tumors carry either the more common t(2;13) PAX3-FOXO1 (PAX3FKHR) or the less common t(1;13) PAX7-FOXO1 (PAX7-FKHR) chromosomal
translocation (2, 3, 6-10), while the rest are alveolar in histology but lack a characteristic
genetic signature. These translocations also carry prognostic implications, and PAX3FOXO1 in particular has been associated with unfavorable outcomes. In one study, the
estimated 5-year survival rates for PAX3-FOXO1, PAX7-FOXO1, and fusion-negative
ARMS were 39%, 74%, and 89%, respectively (11). Another study found that 4-year
survival overall for PAX3-FOXO1 patients was 52% as opposed to 77% for PAX7-FOXO1
patients; even more impressively, the respective 4-year survival rates for those with
metastatic disease were 8% and 75% (10). Within a clinical trial comparing two
chemotherapy protocols, 5-year event-free survival and overall survival rates for fusionnegative ARMS ranged between 80-100%, versus 49-92% for fusion-positive ARMS (9). In
light of these data, the functions of PAX3/7-FOXO1 fusion proteins and their potential as
targets for directed therapy have been the focus of much investigation.
PAX3 and PAX7 are both transcription factors that are critical in tissue development;
PAX3 regulates neural crest development and embryonic skeletal muscle formation, and has
anti-apoptotic effects, while PAX7 plays a larger role in post-natal myogenesis and adult
muscle regeneration (12). FOXO1 is an insulin-regulated forkhead transcription factor that is
involved in the control of glucose metabolism, cell cycle progression, and apoptosis (13).
When fused, PAX3/7-FOXO1 acts upstream via multiple molecular pathways to powerfully
stimulate cellular proliferation, angiogenesis, cellular transformation, and myogenesis, and
inhibit apoptosis and terminal differentiation (7, 14); one such mechanism that has been
proposed for PAX7-FOXO1 is prevention of the downregulation of NF-kB that normally
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occurs with terminal differentiation of muscle cells (14). The wide-ranging consequences of
acting upstream are magnified by the fact that not only are the fusion proteins expressed at
higher levels than wildtype PAX3/7, but also that they are 10- to 100-fold more potent
transcription factors than wildtype PAX3/7 (15). Additionally, unlike wildtype FOXO1,
PAX3/7-FOXO1 does not translocate from the nucleus to the cytoplasm for proteasomal
degradation and instead remains constitutively active (15, 16).
Interestingly, comparisons of ARMS to ERMS as well as of fusion-positive ARMS to
ERMS and fusion-negative ARMS reveal distinct patterns of genetic alterations. In general,
gains of either partial or whole chromosomes, particularly of chromosomes 2, 5, 7, 8, 11, 12,
13, 17, 18, and 19, and less frequently losses of chromosomes 10, 14, 15, 16, and 19, have
been more closely associated with ERMS than with ARMS (17-19); a review of comparative
genomic hybridization analyses concluded that chromosome-level changes—apart from the
obvious t(2;13) and t(1;13) translocations—are indeed less commonly seen in ARMS tumors
(8). These studies have found that instead, ARMS cells exhibit copy-number variations more
commonly than ERMS cells (8, 17-19). Among the amplified genes are CDK4, an oncogene
implicated in a number of malignancies including glioblastoma, liposarcoma, melanoma, and
breast carcinoma; MYCN, a transcription factor associated with neuroblastoma and
retinoblastoma; and MIR17HG, the host gene for a microRNA cluster that is also amplified
in diffuse large B-cell lymphoma and small cell lung carcinoma (8, 18, 20). Also amplified
are genes involved in signaling pathways, such as cell surface receptors WNT1 and PDGFB
(20); tyrosine kinase receptors ErbB2 (20) (amplified in breast and ovarian carcinomas),
ErbB3 (20) (amplified in prostate, bladder, and breast carcinomas), and ALK (21, 22)
(amplified in anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung
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cancer); MAPK cascade player RAF1 (20); and tyrosine kinase PTK2 (20). Some amplified
stretches have also been associated with poorer clinical outcomes for both fusion-positive
and -negative ARMS: IRS2 has anti-apoptotic functions and has been associated with
increased metastatic potential in breast cancer (21), while 2q13-q14 does not correspond with
a known gene (18).
Furthermore, PAX3/7-FOXO1 positive tumor cells have been shown to carry fewer
gene mutations than their fusion-negative counterparts, and it has been suggested that both
this and the limited number of chromosomal changes reflect the critical role of
“transcriptional reprogramming” in the pathophysiology of fusion-positive ARMS (18). The
relatively few mutations that are seen in fusion-positive tumors are usually common to both
subsets of ARMS as well as ERMS; these include genes involved in cell cycle regulation,
protein phosphorylation, DNA repair, muscle cell differentiation, MAPK regulation,
chromatin modification, and induction of apoptosis. Among these are PIK3CA, which
functions in cell proliferation and has been implicated in cervical, papillary thyroid,
squamous cell, and breast carcinomas; BCOR, a transcription repressor that may play a role
in apoptosis; ATM, which regulates the rate of cell division and is also involved in DNA
repair; and ZNF350, which is a transcriptional repressor that has been associated with
neuromas (18). Notably, mutations in RAS are among the most common seen fusionnegative RMS, but have not been found in fusion-positive cells (18, 21).
In light of the relative dearth of mutations in genes classically associated with
malignancy, the true genetic hallmarks of fusion-positive ARMS lie in patterns of gene
expression—the “transcriptional reprogramming” reflective of PAX3/7 and FOXO1’s native
functions as transcription factors—as evidenced through cDNA microarrays, RNA profiles,
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and DNA methylation profiles. Although multiple genes have been found to be universally
upregulated or downregulated in ERMS, fusion-negative ARMS, and fusion-positive ARMS,
a number of affected genes have been specifically associated with PAX3-FOXO1, PAX7FOXO1, or both. Many more upregulated than downregulated genes have been reported in
the literature (6, 14, 23-31). Induced transcriptional targets of functional interest include
MyoD (6, 23, 25), myogenin (25), IGFBP5 (25), PTMA (32), FGFR4 (6, 14, 29, 31),
homeobox genes (27, 29), PTHLH (24), NELL1 (6, 29), ELMO1 (29), CPT1A (27), SLIT2
(24), SLUG (25), and MYCN (6, 28); although the mechanisms by which their protein
products contribute to ARMS’ malignant properties have not been fully elucidated, taken
together they appear to dually repress myogenic differentiation and promote cell survival (6).
A complete list of differentially expressed genes as reported in the literature as of 2013 can
be found in Supplementary Table 1.
Unsurprisingly, a number of these upregulated proteins play roles in myogenesis.
Myogenin and MyoD are both transcription factors that apparently induce the expression of
other genes that regulate muscle growth, energy metabolism, and contractility; of these,
MYL4 is particularly intriguing because it is a fetal muscle gene that is not found in adult
myocytes (25). Myogenin is also known to induce the expression of IGFBP5 in both normal
and PAX3-FOXO1 cells; the protein is secreted during embryonic muscle development, and
binds to IGF1 and IGF2 to modulate their effects on growth. PTMA, which among its
multiple studied functions also has a strong link with cellular growth and survival, has been
associated with myogenic proliferation. Meanwhile FGFR4, normally under the control of
PAX3 and PAX7, is expressed in the very early stages of muscle differentiation. The
upregulation of these genes is in line with the repression of PMX1 (25), which is typically

10

expressed in adult skeletal muscle, and overall with PAX3/7-FOXO1’s ability to inhibit
terminal muscle tissue differentiation.
Also playing a key role in tissue differentiation and overall embryonic development
are the homeobox genes, SLUG, and MYCN. Upregulated in PAX3-FOXO1 cells are
HOXA9 (27, 29), which regulates embryonic gene expression, morphogenesis, and tissue
differentiation; HOXB13 (27), which is involved in fetal skin development and later,
cutaneous regeneration; and HOXD1 (27), which functions in tissue differentiation and limb
development. SLUG is a zinc finger transcriptional repressor that is related to neural crest
and limb bud development as well as epithelial-mesenchymal transitions; importantly, its
protein has anti-apoptotic activity and is also thought to repress E-cadherin transcription in
breast carcinoma. MYCN, also found to be amplified in analyses of copy-number variation,
is expressed in the normal embryo to play critical roles in neurological development.
Associated with enhanced tumor cell migration are PTHLH, NELL1, ELMO1, and
CPT1A. ELMO1 endogenously promotes cytoskeletal rearrangements and phagocytosis, but
the native roles for the other proteins are less intuitive. PTHLH, broadly involved in
endochondral bone development, has been implicated in the metastases of breast carcinomas
and RMS to the bone. NELL1 also plays a role in bone growth and activates components of
the MAPK cascade. Finally, CPT1A, classically understood as a regulatory enzyme in fattyacid oxidation, has more recently been studied in the context of apoptosis and cell
proliferation as well as metastatic potential. Assisting this propensity for increased metastasis
is SLIT2, which not only has a role in axonal guidance but also recruits endothelial cells to
promote angiogenesis.
Despite these wide-ranging transcriptional changes, it has been demonstrated via both
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mouse models and human tissue that PAX3/7-FOXO1 by itself is generally insufficient for
tumorigenesis (7, 18, 25), and in fact isolated overexpression can result in cellular growth
suppression or even death (16, 33). Although the introduction of a fusion gene causes
accelerated growth and occasionally malignant transformations in vitro, preliminary research
in mice has demonstrated that the expression of PAX3-FOXO1 causes developmental
abnormalities such as cardiac and diaphragmatic defects (34), but no muscle tumors (34, 35).
However, tumors are observed in vivo or on soft agar when the fusion proteins are combined
with inactivation of p53 or constitutive Ras pathway activation (35). In human skeletal
muscle cells, PAX3-FOXO1 expression and p16INK4A methylation, the latter which in turn
disables the Rb pathway, act synergistically to allow these cells to more quickly bypass the
“senescence checkpoint” than either of these genetic events alone (33). This checkpoint
typically marks the beginning of a period resulting in terminal differentiation and growth
arrest, though it appears that PAX3-FOXO1 and p16INK4A affects growth only (33). Further
research has shown that p14ARF, another tumor suppressor, is also downregulated in PAX3FOXO1 positive cells; additionally, upregulation of hTERT, involved in telomere
stabilization, and MYCN are required for tumorigenesis in cells expressing PAX3-FOXO1
with p16INK4A and p14ARF loss of function (36).
Other genes upregulated in fusion-positive ARMS cells also appear to depend on the
particular genetic milieu of the tumor. For instance, NELL1 overexpression has been shown
to induce apoptosis in normal myoblasts yet contributes to increased invasiveness in fusionpositive cells, leading to the suggestion that the advantageous effects of NELL1 may be
dependent on the fusion or additional proteins present only in the tumor (29). This further
emphasizes that PAX3/7-FOXO1 positivity does not act alone or independently in
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establishing ARMS’ oncological properties.
That PAX3/7-FOXO1 cells require additional genes to complete their malignant
transformation and subsequently survive suggests that these ARMS cells are dependent on
these and other genes for survival. Indeed, all cancers are characterized by a paradoxical
relationship to DNA repair mechanisms: although they must hijack DNA repair pathways in
order to undergo tumorigenesis, they simultaneously require intact DNA repair pathways in
order to continue to replicate their genetic material and divide; in other words, the tumor
becomes dependent on an intact alternative DNA repair mechanism or cellular survival gene
(37-39). Survival genes encompass all of those that enable cancerous cells to evade immune
surveillance and withstand the additional metabolic, proteotoxic, mitotic, oxidative, and
DNA damage stresses brought on by uncontrolled proliferation and survival (40). This model
of dependency, known as oncogene addiction, has been studied extensively in breast and
ovarian cancers arising from BRCA1 or BRCA2 mutations (38, 41-43). In the case of these
malignancies, PARP1, a critical player in the repair of single-strand breaks, becomes
essential as BRCA1 and BRCA2 can no longer regulate the repair of double-stranded breaks;
without PARP1, double-stranded DNA breaks accumulate, thereby stalling DNA replication
and cell growth (38, 43). PARP1 inhibition has therefore gathered much attention as a
potential therapy, and takes advantage of the related, emerging concept of synthetic lethality.
Synthetic lethality, originally defined over a century ago in Drosophila melanogaster
but not applied to cancer research until fairly recently, refers to a relationship between two
genes in which a mutation in one will not impact a cell’s viability, whereas mutations in both
will result in cell death. The traditional conceptualization centers on two genes that function
in redundant pathways or converge on a common critical pathway, typically in DNA repair
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but also in other processes, in such a way that one can compensate for the loss of the other
(37-39, 41-43). This redundancy is understood to contribute to genetic robustness, which
allows organisms to maintain homeostasis and survive in the face of varied environmental
perturbations and evolutionary challenges (42). An offshoot of synthetic lethality, known as
“synthetic dosage lethality,” refers to a relationship in which one upregulated gene requires
the upregulation of another for the cell to survive (38). Because by definition, healthy cells
should not harbor deactivating or activating mutations in or abnormal levels of expression of
any of these genes, targeting a synthetically lethal gene should affect only the tumor. The
effects can be categorized into two groups: “stress sensitization,” which hampers the cells’
ability to endure the aforementioned five categories of additional stresses, and “stress
overload,” which increases the burden posed by these stresses (40). Both strategies tackle the
significant challenges to effective targeted cancer therapies, the need for which is highlighted
by the fact that the majority of available cancer treatments are extremely toxic to patients.
Currently used chemotherapeutic agents typically have low therapeutic indices and
narrow therapeutic windows, rendering the appropriate dosing of these drugs very difficult
(44). Although most chemotherapies attempt to exploit the fact that cancer cells are growing
and dividing more quickly than their healthy counterparts, they nonetheless target enzymes
that are common to both types of cells and cause well-known side effects such as hair loss
and gastrointestinal upset. Furthermore, the inherent lack of specificity in most existing
chemotherapies opens the door to the development of resistance for which the mechanisms
are unclear; in contrast, knowing the genetic targets enables treatment protocols to anticipate
or even prevent resistance (41). While success stories such as imatinib against BCR-ABL in
chronic myelogenous leukemia exist, in general the search for targeted treatments has been
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elusive. Oncogenes are often more similar to their non-mutated counterparts than not, and
tumor suppressors with loss of function generally cannot be adequately restored via
pharmacological means (37, 40, 41, 44, 45). Harnessing synthetic lethality allows medicine
to sidestep the most obvious target, and it is thus particularly appealing for the treatment of
malignancies characterized by the upregulation of non-kinases such as KRAS, which cannot
be blocked without impairing signaling activity in normal cells (39).
Candidate genes for a synthetically lethal therapeutic target are therefore most likely
upregulated in the tumors of interest, and for fusion-positive ARMS include but are not
limited to those discussed above. Of the genes that comprise ARMS’ genetic signature,
MYCN and the MYC family, which like KRAS are difficult to target but frequently
upregulated in cancer, have been the focus of much investigation albeit in non-RMS
contexts. Previous research has demonstrated that the CDK family is in a synthetically lethal
relationship with overexpressed MYCN. Inhibition of CDK2 in neuroblastoma cells induced
an upregulation of p53 and subsequent apoptosis (46), while inhibition of CDK1 in a panel of
human tumor cell lines caused apoptosis secondary to downregulation of the apoptosis
inhibitor BIRC5 (47). Other studies have shown that AURKB, which regulates mitosis, is
synthetically lethal to MYC and MYCN by inducing apoptosis independently of p53
expression (48, 49). siRNA silencing of GSK3β, a serine-threonine kinase that functions in
the negative regulation of glucose homeostasis and Wnt signaling, causes apoptosis in MYCoverexpressing cells through downstream upregulation and potentiation of the TRAIL death
receptor DR5 (50, 51).
Synthetically lethal relationships for which the molecular mechanisms are less clear
have also been found. Knockdown of TDP1 and inhibition of PARP1, which are both
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components of a larger single-strand DNA break repair complex, results in apoptosis in
ARMS cells, suggesting that these two proteins are compensating for a hitherto unidentified
defective DNA repair mechanism (52). It also enhances the ARMS response to the
topoisomerase I inhibitor camptothecin (52). While the inhibition of two targets before
chemotherapy is unlikely to be clinically feasible, this result exemplifies the wide range of
applications of synthetic lethality, from the identification of specific targets and development
small-molecule inhibitors to increasing the effectiveness of existing therapies. This finding is
also particularly intriguing in light of the fact that fusion-positive ARMS has been shown to
be more responsive to camptothecin therapy than ERMS via a mechanism independent of
topoisomerase I inhibition; it raises the possibility that this chemotherapy acts on a
downstream target of PAX3/7-FOXO1 that is synthetically lethal to the tumor (53), perhaps
related to the same unidentified defective DNA repair mechanism.
While these results are encouraging, the heterogeneity of fusion-positive ARMS
genetics and patient physiologies necessitates further research into additional synthetically
lethal targets. RNAi screens, high-throughput chemical screens, and combined RNAi/smallmolecule screens are the most common approaches to the therapeutic exploitation of
synthetic lethality (54). For the purposes of using synthetically lethal relationships, RNAi
screens typically employ reverse genetics, which starts with the cancer cell line under study
and attempts to detect the functional consequences of inhibiting the expression of a wide
range of genes (42). The results are culled for gene targets that cause such desired effects as
decreased cell viability, motility, and mitotic activity when inhibited in the cell line of
interest but not in others. This thus plays upon oncogene addiction and synthetic lethality but
is notably limited by off-target effects and dose-specific phenotypic responses (42, 45). The
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initial screen is followed by validation of the identified targets in vivo, and, if successful,
high-throughput chemical screens to find existing or new drugs that act upon the genes’
protein products.
It is also possible to bypass the initial step of identifying synthetically lethal genes,
and instead begin with the high-throughput chemical screen to immediately search for
existing drugs that selectively kill the cancer cells of interest without necessarily knowing the
protein target. As in the likely case of camptothecin, this intrinsically exploits a synthetically
lethal relationship. This approach is most limited by off-target effects as well as the fact that
chemical compounds can behave differently in vitro and in vivo, and therefore be unsuitable
for clinical use despite exhibiting desired inhibitory effects in the screen (45, 54). Not
knowing the molecular targets of an identified drug potentially allows for more unanticipated
side effects in vivo, and the process of working in reverse to find the molecular target can be
labor-intensive. The combined RNAi/small-molecule screen attempts to address these
limitations by simultaneously identifying drugs and RNAi knockdowns that achieve the same
phenotype, and cross-comparing the results to find a chemical compound that inhibits the
protein product (45). Although this type of screen is expensive and still comparatively
nascent, knowing the intended target of a drug increases the likelihood that it will meet the
criteria for clinical usability.
RNAi and high-throughput chemical screens are themselves not new research
strategies. Yet applying the concept of synthetic lethality to these methods enhances the
specificity of the results, and in theory increases the yield of the lead optimization process
upon which all three screening tactics converge. Here, it is hoped that by taking advantage of
genetic relationships that are exclusive to fusion-positive ARMS, the relative
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unresponsiveness of these tumors to existing chemotherapy- and radiation-based treatments,
and the consequent poor prognosis, can begin to be addressed.
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II. STATEMENT OF PURPOSE
This thesis aims to create and characterize a stable, inducible PAX3-FOXO1 clonal
cell line in a U2OS background to enable the eventual study of the fusion protein’s
downstream effects with respect to drug response. The validity of this clonal cell line as a
mimic of fusion-positive ARMS will be verified by comparing its cDNA profile for four
proxy genes to those previously reported in the literature and to cDNA data obtained for
U2OS, fusion-negative RMS, and fusion-positive ARMS cell lines.
Fusion status is closely linked to prognosis and patient outcomes in ARMS, and a
greater understanding of the unique properties PAX3/7-FOXO1 confers upon tumor cells is
likely key to the development of better therapies. The PAX3-FOXO1 inducible cell line
allows for the investigation of the fusion protein’s effects in isolation, independent of other
genetic changes that may be common to both fusion-positive and -negative ARMS. More
precisely, this allows for the identification of genetic relationships that are synthetically
lethal to PAX3-FOXO1 specifically.
Ultimately, these clonal cell lines will be used alongside control ARMS, ERMS, and
U2OS cells in a high-throughput chemical screen to identify drug compounds that selectively
kill PAX3-FOXO1 expressing cells. It is hoped that this will eventually lead to the
development of treatments that are less toxic and more effective than what surgery,
chemotherapy, and radiation can currently offer.
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III. METHODS
Cell lines and culture conditions. U2OS (osteosarcoma) (55), RD (ERMS) (56), Rh18
(fusion-negative ARMS) (56), Rh30 (t(2;13)-positive ARMS) (56), and Rh41 (t(2;13)positive ARMS) (56) cells have been previously described in the literature. U2OS and RD
cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) with Lglutamine and 4.5 g/L D-glucose containing 10% tetracycline-tested fetal bovine serum
(FBS, Gibco), and Rh18, Rh30, and Rh41 cells were cultured in Roswell Park Memorial
Institute 1640 Medium (RPMI, Gibco) with L-glutamine containing 10% FBS. The Tet-On
3G U2OS cell line was cultured in DMEM with L-glutamine and 4.5 g/L D-glucose,
containing 10% FBS and 10 mg/mL blasticidin. The PAX3-FOXO1 clonal cell line as well
as all clonal cell line candidates were cultured in DMEM with L-glutamine and 4.5 g/L Dglucose, containing 10% FBS, 10 mg/mL blasticidin, and 10 mg/mL puromycin. Expression
of PAX3-FOXO1 was induced with 10 mg/ml doxycycline. All cells were maintained at
37°C with 5% CO2. Unless otherwise indicated, all cells were washed with Dulbecco’s
Phosphate Buffered Saline (PBS, Gibco) and trypsinized with Trypsin-EDTA (0.25%)
(Gibco).
Creation of PAX3-FOXO1 positive clonal cell line. PAX3-FOXO1 was chosen as the fusion
protein of study because it is more prevalent than PAX7-FOXO1 in the ARMS patient
population and has been associated with the worst clinical outcomes. The PAX3-FOXO1
sequence was obtained from the Barr Lab (National Cancer Institute) and amplified by PCR
using

the

primers

5’-GATTATTATTAATCACCATGACCACGCTGGCC-3’

and

3’-CACTAACCCATTAATTCAGCCTGACACCCAGC-5’ with CloneAmp HiFi PCR
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Premix (Clontech Laboratories). The reaction was run in the C1000 Touch Thermal Cycler
(Bio-Rad Laboratories) under the following conditions: 95°C × 3 minutes, [98°C × 30
seconds, 65°C × 30 seconds, 72°C × 150 seconds] × 34 cycles, and 72°C × 5 minutes. After
purification with the QIAquick PCR Purification Kit (Qiagen Corporation), the PCR products
were cut with the restriction enzyme AseI (New England Biolabs (NEB)) under the
manufacturer’s suggested conditions (NEBuffer 3, incubated @ 37°C × 2 hours in the C1000
Touch Thermal Cycler). A pTRE-Tight vector (Clontech) was simultaneously cut with the
restriction enzyme NdeI (NEB), again under the manufacturer’s suggested conditions
(NEBuffer 4, incubated @ 37°C × 2 hours). Both restriction-digest products were gelpurified using the QIAquick Gel Extraction Kit (Qiagen), modifying the manufacturer’s
instructions to omit the addition of isopropanol and the optional Buffer QG wash. The pTRETight vector was then dephosphorylated with Antarctic Phosphatase (NEB) according to
NEB protocol (incubated @ 37°C × 15 minutes). Following PCR purification of the vector
with the QIAquick PCR Purification Kit, PAX3-FOXO1 was ligated into pTRE-Tight using
T4 DNA Ligase (NEB) with the insert and vector in a 3.5:1 ratio.
The resulting plasmid was transformed into XL10-Gold Ultracompetent Cells
(Agilent Technologies) per manufacturer specifications, and the cells were grown on soft
agar with ampicillin overnight @ 37°C. Ten colonies were subsequently inoculated, and the
plasmid was harvested from the bacteria using the QIAprep Spin Miniprep Kit (Qiagen). The
ten plasmid samples were cut with the restriction enzyme HindIII (NEB) under the
manufacturer’s suggested conditions (NEBuffer 2, incubated @ 37°C × 2 hours), and the
resulting products were run a 1% agarose ethidium bromide gel to verify that the PAX3FOXO1 fusion gene was in the correct orientation within the vector. Of the ten samples
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tested, two yielded the two bands of the expected size (2429 and 2948 bp). These two
plasmids were sequenced at the Keck DNA Sequencing Facility (Yale School of Medicine)
using the forward primer 5’-GATTATTATTAATCACCATGACCACGCTGGCC-3’ for
additional confirmation that the pTRE-Tight vector contained PAX3-FOXO1 in the correct
orientation. This primer was directed against the PAX3-FOXO1 gene itself because of poor
sequencing performance with primers directed against the pTRE-Tight vector. To check for
point mutations within PAX3-FOXO1, the two plasmids were again sequenced, this time
with four separate forward primers targeted to sequential segments of the fusion gene (5’GACGCGGTCTGTGATCGAAACA-3’, 5’-CTATACAGACAGCTTTGTGCCTC-3’, 5’CACCAGTTTGAATTCACCCAG-3’, 5-CTTCTCCACCAGGAGAAGCTC-3’) as well as
one reverse primer (3’-GTACCTGCACAGGATCTTGGAGAC-5’). Based on these results,
one of the two PAX3-FOXO1/pTRE-Tight plasmid candidates was selected for further use.
This plasmid was introduced into a U2OS cell line that stably expresses the Tet-On
3G transactivator (Clontech), received from the Jensen Lab (Yale School of Medicine).
U2OS was selected as the host cell as it is a well-characterized cell line representative of
mesenchymal tumors. Moreover, while multiple previous studies have chosen ERMS cells to
serve as the host for inducible PAX3/7-FOXO1 systems based on the rationale that they
better represent the overall milieu of ARMS cells, it was felt that U2OS cells provide a
cleaner genetic background against which to study the effects of the fusion protein in
isolation.
1 × 106 Tet-On 3G U2OS cells suspended in 100 µL Amaxa solution (Lonza Group)
were nucleofected with 1 µg of the PAX3-FOXO1/pTRE-Tight construct and 50 ng of linear
puromycin marker (Clontech). They were then plated on a 10-cm dish, with addition of
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blasticidin and puromycin 24 hours later; the plates were then incubated until discrete
colonies could be picked for growth in 96- and then 48-well plates. At this stage, each well
was split into two wells of a 24-well plate. One well per clone was incubated with
doxycycline for 24 hours before all cells were harvested for PAX3-FOXO1 expression
screening by Western blot using anti-FOXO1 monoclonal antibody (Cell Signaling, C29H4).
In total, over 90 candidates were screened.
Western blot protocol. All cells were lysed in 100-200 µL of RIPA buffer (50 mM HEPES,
250 mM NaCl, 5 mM EDTA, 1% NP40, H2O to 50 mL) with protease inhibitor cocktail
(Boehringer Mannheim Corporation). The samples were sonicated using the EpiShear MultiSample Sonicator/Chiller (Active Motif) for six cycles of 10 seconds on and 10 seconds off
at 100% amplitude. The samples were then incubated at 95°C for 5 minutes and then
centrifuged at room temperature for 1 minute. All samples were subsequently maintained at
4°C unless otherwise indicated.
To ensure equal loading of the protein, the sample concentrations were measured by
Bradford assay (Bio-Rad) using the Synergy 2 microplate reader (BioTek Instruments
Incorporated). The samples were diluted to a concentration of 1:10 in RIPA buffer, then
prepared according to the manufacturer’s Standard Procedure for Microtiter Plates and
assessed in duplicate; five standards of 0.05 µg/µL, 0.1 µg/µL, 0.2 µg/µL, 0.4 µg/µL, and 0.5
µg/µL were used.
Each sample was prepared for loading with a target protein load of 25 µg, 1 mM of
DTT (American Bioanalytical Incorporated), 8.25 µL of NuPAGE LDS Sample Buffer (4x)
(Novex), and RIPA buffer to a total volume of 33 µL. Samples were run on 4-12% Bis-Tris
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Protein Gels (Novex) in NuPAGE MOPS SDS running buffer (50 mM MOPS, 50 mM Tris
base, 1 mM EDTA, 0.1% SDS to pH 7.7) at 100 mV. The proteins were transferred overnight
at 33 mV at 4°C, using Immobilon-P transfer membrane (Millipore Corporation) and Mini
Trans-Blot filter paper (Bio-Rad) with NuPAGE transfer buffer (25 mM bicine, 25 mM BisTris, 1 mM EDTA, 20% methanol to pH 7.2) in the Mini Trans-Blot Electrophoretic Transfer
Cell (Bio-Rad).
Following transfer, membranes were incubated in 5% milk in TBST (50 mM Tris-Cl,
150 mM NaCl to pH 7.6) for 1 hour, in primary antibody (anti-FOXO1 monoclonal antibody
(Cell Signaling, C29H4) or anti-SMC1 monoclonal antibody (Abcam, ab21583)) in TBST
for 1 hour, and in secondary antibody (anti-rabbit HRP-linked antibody (Cell Signaling,
7074)) in TBST for 1 hour. All incubations were carried out at room temperature, and
membranes were washed four times for 10 minutes each between incubation steps.
Membranes probed with a second primary antibody were first stripped with Restore PLUS
Western Blot Stripping Buffer (Thermo Fisher Scientific) for 5 minutes at room temperature
before the above protocol, starting with incubation in 5% milk, was repeated. All blots were
developed using Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare
Life Sciences), and analyzed using the ChemiDoc MP Imaging System and Image Lab
software (Bio-Rad) per the manufacturers’ protocols.
Validation of PAX3-FOXO1-positive clonal cell line as ARMS mimic. TaqMan (Thermo
Fisher) data were obtained for Tet-On 3G U2OS, RD, Rh18, Rh30, Rh41, and the inducible
PAX3-FOXO1 clonal cell lines to verify that the downstream genetic effects of PAX3FOXO1 expression in the clone mirror those seen in fusion-positive ARMS cells. Three
genes—DAPK (23, 31), FGFR4 (6, 14, 29, 31), and MyoD (6, 23, 25)—were selected as
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proxies for global gene expression changes based on data previously reported in the literature
and the proteins’ native functions. Of note, GREM1 (23, 28, 29) was also initially selected as
a proxy gene, but CT values consistently failed to be read and the TaqMan probe was still
under quality control investigation by the manufacturer at the time of writing.
RNA was obtained from the five control cell lines as well as uninduced and
doxycycline-induced PAX3-FOXO1 clonal cells with the RNeasy Mini Kit (Qiagen
Corporation). One pellet of approximately 10 × 106 cells was harvested per cell line, and
suspended in 600 µL of Buffer RLT per manufacturer protocol. The optional DNase
digestion and RNeasy spin column drying steps were included. Following RNA isolation, the
purity of the samples were confirmed by NanoDrop (ThermoScientific) with a 260/280 nm
ratio of ~2.0.
cDNA was generated from this RNA using the High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems) as per manufacturer protocol and using the C1000
Touch Thermal Cycler. For each 20 µL reaction, the upper limit of 2 µg of RNA was used.
The resulting cDNA was subsequently used for a TaqMan assay (Applied Biosystems) with
probes (Applied Biosystems) for DAPK (assay ID# Hs00234489_m1), FGFR4 (assay ID#
Hs01106908_m1), MyoD (assay ID# Hs00159528_m1), and a reference (actin or 18S). Each
PCR reaction contained the amount of cDNA resulting from 2 µg of corresponding RNA. All
samples were run in triplicate per assay under the following conditions in the Mx3000P RealTime PCR System (Agilent Technologies): 50°C × 2 minutes, 95°C × 10 minutes, and [98°C
× 15 seconds, 60°C × 60 seconds] × 45 cycles. The data was processed using the
accompanying MxPro QPCR software (Agilent Technologies).
The TaqMan assay was performed a total of three times. The first assay (“TaqMan
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1”) tested RD, Rh30, and Rh41 control cells as well as uninduced and doxycycline-induced
(72 hours) PAX3-FOXO1 clonal cells, and primarily served to validate the use of the DAPK,
FGFR4, and MyoD probes. The second assay (“TaqMan 2”) tested RD, Rh18, Rh30, and
Rh41 cells to further establish the relative levels of gene expression in the controls. Finally,
the third assay (“TaqMan 3”) tested Tet-On 3G U2OS, PAX3-FOXO1 clonal cells harvested
after culture -/+ doxycycline induction for 72 hours, and PAX3-FOXO1 clonal cells
harvested after culture -/+ induction for approximately two months.
The data for the RD, Rh18, Rh30, and Rh41 cell lines from TaqMan 1 and TaqMan 2
were used to verify that DAPK, FGFR4, and MyoD are significantly upregulated in fusionpositive ARMS cells and therefore valid proxies for confirming that the inducible PAX3FOXO1 clonal cell line is a fusion-positive ARMS mimic. For each tested gene within an
assay, the individual CT values were normalized to the averaged CT value for the reference
gene (actin or 18S) for the corresponding cell line (individual CT of tested gene – average CT
of reference gene) to generate three ΔCT values per gene per cell line. These ΔCT values were
compared using the unpaired t-test (http://graphpad.com/quickcalcs/ttest1/) in order to
demonstrate that the three genes are significantly upregulated in Rh30 and Rh41 cells as
compared to RD and Rh18 cells. Mean ΔCT values for each gene within each cell line were
also calculated by averaging the CT values from the triplicate samples and normalizing this
value to the average CT value of the reference gene of the corresponding cell line (average CT
of tested gene – average CT of reference gene).
Following this, the data from TaqMan 1 and TaqMan 3 were used to assess the
uninduced and doxycycline-induced PAX3-FOXO1 clonal cells in several ways. Mean ΔCT
values were first calculated for each gene per cell line condition as above. These values were
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used to assess for statistically significant differential expression levels of DAPK, FGFR4,
and MyoD in the clonal cell line compared to Tet-On 3G U2OS cells as well as to the four
RMS control cell lines, again using the unpaired t-test. Additionally, the mean ΔCT values
were used to calculate ΔΔCT values for each gene per doxycycline-induction time condition
(72 hours or two months) by comparing the average ΔCT for the control (uninduced) and
experimental (induced) cell populations (ΔCT uninduced – ΔCT induced). The fold-change in
target gene expression level was calculated as 2^(ΔΔCT).
Clonigenic survival assay of U2OS cells for future use in validating drug screen hits. A
preliminary clonigenic survival assay of U2OS cells treated with etoposide was performed in
order to verify the experimental conditions for future use in the validation of hits from the
high-throughput chemical screen. U2OS cells were grown under the conditions described
above to approximately 80% confluence on 25 10-cm plates, then incubated overnight in the
presence of varying concentrations of etoposide (5 plates each for 0.1 µM, 1 µM, 5 µM, and
10 µM) or DMSO (hereafter labeled 0 µM). Following incubation, the cells for each drug
concentration were trypsinized and combined in 2 mL of DMEM. Each of the five cell
suspensions was counted in quadruplicate using the TC20 Automated Cell Counter (Bio-Rad
Laboratories). These suspensions were then diluted to 9 × 105 cells/mL in 2 mL, then
subsequently diluted to 9 × 103 cells/mL in 10 mL (1:10 dilution) and 4.5 × 103 cells/mL in
12 mL (1:2 dilution). The five 4.5 × 103 cells/mL stock solutions were serially diluted five
times at a ratio of 1:3 to generate additional stock solutions of 1.5 × 103 cells/mL, 5 × 102
cells/mL, 1.665 × 102 cells/mL, 55.5 cells/mL, and 18.5 cells/mL per drug concentration. Of
note, only the 4.5 × 103 cells/mL and 1.5 × 103 cells/mL stock solutions were created for the
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10 µM-treated cells due to poor survival and low cell counts. 2 mL of each stock solution
was plated in triplicate into 6-well plates, resulting in three 6-well plates per drug
concentrations 0-5 µM and one 6-well plate for drug concentration 10 µM, and 13 plates for
the assay overall.
The cells were incubated under standard conditions for 12 days before they were
stained twice with crystal violet. Excess crystal violet solution was removed from the plates
in a distilled water bath, and then allowed to air dry for approximately 24 hours. The stained
colonies were manually counted.
The U2OS response to etoposide treatment was calculated as follows. The number of
colonies in the triplicate wells per experimental condition were averaged, and then divided by
the number of cells originally plated in order to calculate the fraction of cells that survived.
For the control 0 µM condition only, all of these fractions were averaged in order to calculate
the plating efficiency for the entire assay. Each calculated ratio of cells that survived was
divided by this plating efficiency to generate a survival factor for each experimental
condition (six original cell numbers per etoposide dose). The means of the survival factors
for each dose of etoposide were then calculated to determine the overall U2OS dose-response
to the drug.
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IV. RESULTS
Tetracycline-inducible expression of PAX3-FOXO1 in U2OS clonal cell line. U2OS cells
with conditional PAX3-FOXO1 expression were derived, as described in detail in the
Methods. Although the intensity of the band corresponding to PAX3-FOXO1 (Figure 1)
suggests that PAX3-FOXO1 levels are supra-physiological, the results of the TaqMan assays
(Tables 1a vs. 2a vs. 3a vs. 4a), as further discussed below, indicate that downstream effects
are on par with or even below what is observed in fusion-positive ARMS cells. The
conditional induction of PAX3-FOXO1 expression provides an isogenic background with
which to compare the effects of this fusion protein on gene expression and, in the future, the
response to chemotherapeutic drug compounds.

+

–

*

RD

97 kDa

–

Rh41

+

Clone 2

Rh30

Clone 1

WB: FOXO1

Figure 1. Western blot showing tetracycline-inducible PAX3-FOXO1 expression in U2OS
clonal cell line. Whole-cell lysate samples were prepared and run as outlined in the Methods,
and probed with anti-FOXO1 monoclonal antibody. +/- indicates doxycycline induction for
72 hours. Clone 1 positive for inducible expression of PAX3-FOXO1, indicated by * at
expected size of ~97 kDa; Clone 2 negative for inducible expression. Rh30 and Rh41 are
fusion-positive ARMS (positive control); RD is fusion-negative ERMS (negative control).
Non-specific bands shown in place of SMC1 loading control.
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The long-term stability of inducible expression of PAX3-FOXO1 was also tested.
Unfortunately, despite robust levels of PAX3-FOXO1 for the first several weeks after the
identification of the fusion-positive clone, expression begins to fall markedly thereafter
(Figures 2a and 2b). However, the experiments for differential gene expression after transient
transfection or in inducible systems of PAX3/7-FOXO1, as reported in the literature, were all
conducted on a time scale of hours to several days after introduction of the fusion protein (23,
24, 28, 57); this is well within the window of stable expression for the cell line derived here.
In addition, this loss of PAX3-FOXO1 expression over time incidentally allows for the
investigation of the persistence of gene expression changes even after the fusion protein is
essentially removed, as discussed below.

2 Weeks

4 Weeks

–

–

+

+

150 kDa
97 kDa

WB: SMC1
*

*

WB: FOXO1

Figure 2a. Western blot showing gradual loss of tetracycline-inducible PAX3-FOXO1
expression in U2OS clonal cell line. Whole-cell lysate samples, from cells kept in culture for
two and four weeks after initial validation of the clone, were prepared and run as outlined in
the Methods, and probed with anti-FOXO1 monoclonal antibody followed by anti-SMC1
monoclonal antibody for loading control. -/+ indicates doxycycline induction for length of
time indicated.
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Tet-On 3G
U2OS

2 Weeks

2 Months

–

–

+

150 kDa
97 kDa

+
WB: SMC1

*

WB: FOXO1

2b. Western blot showing complete loss of tetracycline-inducible PAX3-FOXO1
expression in U2OS clonal cell line. Whole-cell lysate samples, from cells kept in culture for
two weeks and two months after initial validation of the clone, were prepared and run as
outlined in the Methods, and probed with anti-FOXO1 monoclonal antibody followed by
anti-SMC1 monoclonal antibody. -/+ indicates doxycycline induction for length of time
indicated.
Validation of inducible PAX3-FOXO1 clonal cell line as fusion-positive ARMS mimic. The
TaqMan assays to assess the validity of the inducible PAX3-FOXO1 U2OS clonal cell line,
using DAPK, FGFR4, and MyoD as proxies for differential expression across the genome,
yielded mixed but overall encouraging results. A comparison of CT values from TaqMan 1
(Tables 1a and b) and TaqMan 2 (Tables 2a and b) for RD, Rh18, Rh30, and Rh41 cells
confirmed that DAPK, FGFR4, and MyoD are in general upregulated in fusion-positive
ARMS cells and therefore can be used to assess the inducible PAX3-FOXO1 clonal cell line.
However, a number of caveats to these data must be noted. First, in TaqMan 1, the
upregulation of DAPK in Rh41 cells relative to RD cells does not reach statistical
significance (p-value < 0.05) (Table 1b), but in TaqMan 2 demonstrates a clear difference
(Table 2b). Second, in TaqMan 1, the relative level of MyoD is higher than actin, as
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represented by the negative ΔCT value, in Rh41 cells (Table 1a); this seems intuitively
incorrect, and such a phenomenon is not seen in TaqMan 2 although the reference gene in
this case was 18S (Table 2a). Finally, the upregulation of MyoD in Rh30 cells relative to RD
cells just reaches statistical significance in TaqMan 1 (Table 1b), but fails to do so in
TaqMan 2 (Table 2b). Despite these inconsistencies, the data overall appeared to align with
the literature and validate the decision to use DAPK, FGFR4, and MyoD, and so analysis of
the inducible PAX3-FOXO1 cell line using these probes was performed.

RD

Rh30

Rh41

DAPK

FGFR4

MyoD

6.017

13.330

2.213

(± 0.451)

(± 1.258)

(± 0.471)

2.690

5.767

0.190

(± 0.509)

(± 1.022)

(± 0.410)

5.677

8.260

-0.140

(± 0.439)

(± 1.427)

(± 0.490)

Table 1a. ΔCT values (± SD) from TaqMan 1 for DAPK, FGFR4, and MyoD expression in
control cell lines. CT values from triplicate runs averaged, and then normalized to averaged
actin CT for corresponding cell line (average CT of tested gene – average CT of actin).

vs. RD

DAPK

FGFR4

MyoD

Rh30

0.0011

0.0010

0.0050

Rh41

0.4023

0.0114

0.0039

1b. p-values for ΔCT values from TaqMan 1 for DAPK, FGFR4, and MyoD
upregulation in Rh30 and Rh41 cells compared to RD cells. Individual CT values were
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normalized to the average CT value for actin for the corresponding cell line (CT of tested gene
– average CT of actin), and the resulting ΔCT values for Rh30 and Rh41 were compared to
those for RD using the unpaired t-test.

RD

Rh18

Rh30

Rh41

DAPK

FGFR4

MyoD

15.707

15.900

14.533

(± 0.012)

(± 0.066)

(± 1.246)

17.380

16.237

25.347

(± 0.070)

(± 0.102)

(± 0.042)

15.127

13.913

13.760

(± 0.079)

(± 0.091)

(± 0.047)

9.023

8.503

6.427

(± 0.103)

(± 0.196)

(± 0.157)

Table 2a. ΔCT values (± SD) from TaqMan 2 for DAPK, FGFR4, and MyoD expression in
control cell lines. Calculations performed as in Table 1a, but normalized to 18S.

vs. RD

DAPK

FGFR4

MyoD

Rh30

0.0002

<0.0001

0.3432

Rh41

<0.0001

<0.0001

0.0004

vs. Rh18

DAPK

FGFR4

MyoD

Rh30

<0.0001

<0.0001

<0.0001

Rh41

<0.0001

<0.0001

<0.0001

2b. p-values for ΔCT values from TaqMan 2 for DAPK, FGFR4, and MyoD
upregulation in Rh30 and Rh41 cells compared to RD and Rh18 cells. Individual CT values
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were normalized to the average CT value for 18S for the corresponding cell line (CT of tested
gene – average CT of 18S), and the resulting ΔCT values for Rh30 and Rh41 were compared
to those for RD and Rh18 using the unpaired t-test.
In TaqMan 1, the expression of DAPK, FGFR4, and MyoD shows at least a two-fold
increase after induction of PAX3-FOXO1 expression for 72 hours (Table 3b). However, the
results are limited by the fact that no CT values were read for two of the uninduced and one
of the induced PAX3-FOXO1 samples for FGFR4, and therefore no standard deviation could
be calculated for the ΔCT or ΔΔCT for this gene.

PAX3-FOXO1 Clone (-)

PAX3-FOXO1 Clone (+)

DAPK

FGFR4

MyoD

17.877

25.200

15.120

(± 0.554)

(± N/A)

(± 0.593)

13.693

23.887

13.380

(± 0.372)

(± 2.729)

(± 0.405)

Table 3a. ΔCT values (± SD) from TaqMan 1 for DAPK, FGFR4, and MyoD expression in
uninduced and induced PAX3-FOXO1 clonal cells. Calculations performed as in Table 1a.
-/+ indicates doxycycline induction for 72 hours.

ΔΔCT
Fold-change in expression

DAPK

FGFR4

MyoD

4.183

1.313

1.740

(± 0.667)

(± N/A)

(± 0.718)

18.168

2.485

3.340

3b. ΔΔCT (± SD) and corresponding fold-changes in gene expression after induction
of PAX3-FOXO1 expression, derived from TaqMan 1 data for DAPK, FGFR4, and MyoD.
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ΔΔCT calculated as (ΔCT uninduced – ΔCT induced); ΔCT values derived in 3a. Fold-change
in expression calculated as 2^(ΔΔCT). Level of gene expression compared for PAX3-FOXO1
clonal cell line -/+ doxycycline induction for 72 hours.
The results of TaqMan 3 are both unexpected and encouraging. The most surprising
finding was that DAPK, FGFR4, and MyoD have significantly lower levels of expression in
both the uninduced and induced PAX3-FOXO1 clonal cell line conditions compared to the
Tet-On 3G U2OS cells (Tables 4a and 4b). Although it was assumed that the uninduced
PAX3-FOXO1 clonal cells would geerally share a genetic profile with the control Tet-On 3G
U2OS cells, the expression of these three genes is lower in the clonal cell line compared to
not only the Tet-On 3G U2OS cells but also RD, Rh18, Rh30, and Rh41 cells (Tables 2a, 4a,
and 4c). This possibly suggests that the perturbation associated with PAX3-FOXO1 insertion
may have disrupted normal levels of transcriptional activity. However, both the uninduced
and induced PAX3-FOXO1 cells grow robustly and at approximately the same rate as the
Tet-On 3G U2OS cells in culture, and with the same morphology, providing reassurance that
whatever perturbation this may be is not disruptive to normal cellular function.
TaqMan 3 also shows that induction of the fusion protein is likely sufficient to induce
ARMS-like genetic changes in the clonal cell line, and that sustained expression of PAX3FOXO1 is necessary to maintain these changes. Both DAPK and MyoD are significantly
upregulated in the cells induced with doxycycline for 72 hours; interestingly, however,
FGFR4 sees a significant downregulation in the PAX3-FOXO1 induced state, which is
inconsistent with the literature (6, 14, 29, 31) and also intuitively inconsistent with its known
functions. The limited results of TaqMan 1, which imply that FGFR4 is upregulated in
PAX3-FOXO1 expressing cells (Table 3b), better align with what would be expected of an
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ARMS cell, but overall it is difficult to interpret the results for this gene without additional
data from repeat experiments. On the other hand, none of the three genes tested demonstrate
a significant difference in expression levels between the uninduced and induced cells that had
been incubated for two months but lost PAX3-FOXO1 expression approximately one month
prior to the assay (Table 4d).

Tet-On 3G U2OS

PAX3-FOXO1 Clone (-), 72 hours

PAX3-FOXO1 Clone (+), 72 hours

PAX3-FOXO1 Clone (-), 2 months

PAX3-FOXO1 Clone (+), 2 months

DAPK

FGFR4

MyoD

15.827

9.567

18.387

(± 0.226)

(± 0.130)

(± 1.714)

28.843

19.247

26.180

(± 0.180)

(± 0.026)

(± 0.110)

24.740

19.777

25.057

(± 0.064)

(± 0.070)

(± 0.104)

28.843

19.247

26.180

(± 0.067)

(± 0.187)

(± 0.269)

27.710

19.660

26.320

(± 0.244)

(± 0.084)

(± 0.160)

Table 4a. ΔCT values (± SD) from TaqMan 3 for DAPK, FGFR4, and MyoD expression in
Tet-On 3G U2OS, and uninduced and doxycycline-induced PAX3-FOXO1 clonal cells.
Calculations performed as in Table 1a, but normalized to 18S. -/+ indicates doxycycline
induction for length of time specified, although with decline in PAX3-FOXO1 expression
after ~1 month in the 2-month samples.

vs. Tet-On 3G U2OS

DAPK

FGFR4

MyoD

PAX3-FOXO1 Clone (-), 72 hours

<0.0001

<0.0001

0.0014
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PAX3-FOXO1 Clone (+), 72 hours

<0.0001

<0.0001

0.0025

PAX3-FOXO1 Clone (-), 2 months

<0.0001

<0.0001

0.0016

PAX3-FOXO1 Clone (+), 2 months

<0.0001

<0.0001

0.0013

4b. p-values for ΔCT values from TaqMan 3 for DAPK, FGFR4, and MyoD levels in
uninduced and doxycycline-induced PAX3-FOXO1 clonal cells, compared to Tet-On 3G
U2OS cells. Individual CT values were normalized to the average CT value for 18S for the
corresponding cell line (CT of tested gene – average CT of 18S), and the resulting ΔCT values
for the inducible PAX3-FOXO1 cells under four experimental conditions were compared to
those for Tet-On 3G U2OS using the unpaired t-test. -/+ indicates doxycycline induction for
length of time specified, although with decline in PAX3-FOXO1 expression after ~1 month
in the 2-month samples.

vs. RD

DAPK

FGFR4

MyoD

PAX3-FOXO1 Clone (-), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (-), 2 months

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 2 months

<0.0001

<0.0001

<0.0001

vs. Rh18

DAPK

FGFR4

MyoD

PAX3-FOXO1 Clone (-), 72 hours

<0.0001

<0.0001

0.0003

PAX3-FOXO1 Clone (+), 72 hours

<0.0001

<0.0001

0.0111

PAX3-FOXO1 Clone (-), 2 months

<0.0001

<0.0001

0.0157

PAX3-FOXO1 Clone (+), 2 months

<0.0001

<0.0001

0.0005
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vs. Rh30

DAPK

FGFR4

MyoD

PAX3-FOXO1 Clone (-), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (-), 2 months

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 2 months

<0.0001

<0.0001

<0.0001

vs. Rh41

DAPK

FGFR4

MyoD

PAX3-FOXO1 Clone (-), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 72 hours

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (-), 2 months

<0.0001

<0.0001

<0.0001

PAX3-FOXO1 Clone (+), 2 months

<0.0001

<0.0001

<0.0001

4c. p-values for ΔCT values from TaqMans 2 and 3 for DAPK, FGFR4, and MyoD
levels in uninduced and doxycycline-induced PAX3-FOXO1 clonal cells, compared to RD,
Rh18, Rh30, and Rh41 cells. Individual CT values were normalized to the average CT value
for 18S for the corresponding cell line (CT of tested gene – average CT of 18S), and the
resulting ΔCT values for the inducible PAX3-FOXO1 cells under the four experimental
conditions were compared to those for the established RMS cell lines using the unpaired ttest. -/+ indicates doxycycline induction for length of time specified, although with decline in
PAX3-FOXO1 expression after ~1 month in the 2-month samples.

ΔΔCT, 72 hours
Fold-change in expression, 72 hours

DAPK

FGFR4

MyoD

4.103

-0.530

1.123

(± 0.191)

(± 0.075)

(± 0.151)

17.188

0.692

2.178
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ΔΔCT, 2 months
Fold-change in expression, 2 months

0.033

0.197

0.340

(± 0.253)

(± 0.205)

(± 0.313)

1.023

0.873

0.790

4d. ΔΔCT (± SD) and corresponding fold-changes in gene expression after induction
of PAX3-FOXO1 expression, derived from TaqMan 3 for DAPK, FGFR4, and MyoD.
Calculations performed as in Table 3b, but normalized to 18S; ΔCT values derived in 4a.
Levels of gene expression compared for PAX3-FOXO1 U2OS clonal cell line -/+
doxycycline induction for length of time specified, in PAX3-FOXO1 expression after ~1
month in the 2-month samples.
Clonigenic survival assay. U2OS cells demonstrate a dose-dependent response to overnight
treatment with etoposide (Table 5 and Figure 3), with the greatest incremental effect noted
between the 0 µM and 0.1 µM conditions. In addition to the poor cellular survival for the 10
µM condition at the outset of the experiment as noted in the Methods, the data faces two
limitations. First, the cells were too confluent in the wells originally plated with 9 × 103 cells
for the 0 µM and 0.1 µM treatment conditions and were therefore not included in the final
calculations. Second, there were no surviving colonies in the wells originally plated with 111
cells for the 1 µM and 5 µM treatment conditions, nor in the wells originally plated with 37
cells for the 0.1 µM, 1 µM, and 5 µM treatment conditions; these were also omitted from the
final calculations rather than being factored in as an individual survival factor of 0, as it
seemed much more likely that the killing was non-specific rather than 100% effective at
these drug concentrations. Yet even these limiting factors are consistent with a dosedependent response to etoposide, and thus omission of the over-confluent and empty wells
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diminishes the slope of the survival curve shown.

Etoposide Dose (µM)

0

0.1

1

5

10

Mean Survival Factor

1.000

0.374

0.190

0.157

0.113

(± 0.279)

(± 0.176)

(± 0.051)

(± 0.080)

(± 0.042)

Table 5. Mean survival factors (± SD) of U2OS cells following overnight etoposide treatment
at five different doses and 12 days of growth. Mean survival factor was calculated by
averaging the individual ratios of surviving to plated cells for each etoposide concentration,
divided by the plating efficiency for the assay overall (the mean of the individual ratios for
the 0 µM condition).

1.40

Mean Survival Factor

1.20
1.00
0.80
0.60
0.40
0.20
0.00
0

0.1

1

5

10

Etoposide Dose (µM)

Figure 3. Survival curve of U2OS cells following overnight etoposide treatment at five
different doses and 12 days of growth. See Table 5 for mean survival factor calculations and
values. SDs of mean survival factors denoted by error bars.
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V. DISCUSSION
An inducible PAX3-FOXO1 clonal cell line was created in U2OS cells using the TetOn 3G and pTRE-Tight systems, and their validity as genetic mimics of fusion-positive
ARMS cells was tested via cDNA analysis. Overall, the results of the TaqMan assays suggest
that a 72-hour doxycycline induction of PAX3-FOXO1 expression in the cell line created
here is sufficient to trigger the global changes in gene expression seen in fusion-positive
ARMS cells, as represented by the upregulation in DAPK and MyoD, and possibly FGFR4.
The differences in ΔCT values between the uninduced and doxycycline-induced states reach
statistical significance for DAPK and MyoD in both TaqMan assays performed, with a
statistically significant greater than 17-fold increase for DAPK and greater than two-fold
increase for MyoD between the uninduced to the induced states. The results for FGFR4 show
likely upregulation in one TaqMan assay and downregulation in the other, and require further
follow-up. GREM1 will also most likely be re-added in the future to provide additional
support for the validity of using this clonal cell line for drug screens.
As mentioned above, the Western blots of the doxycycline-induced PAX3-FOXO1
whole cell lysates seem to suggest that the expression levels of the fusion protein are above
physiological levels. However, a comparison of ΔCT values for the inducible cell line and the
Tet-On 3G U2OS, RD, Rh18, Rh30, and Rh41 cells indicates that the levels of DAPK,
FGFR4, and MyoD are below physiological levels even in the doxycycline-induced state,
providing reassurance that this system does not overestimate the effect of the fusion protein
in the endogenous setting. In fact, the fact that the expression levels are lower than for the
fusion-negative controls (Tet-On 3G U2OS, RD, and Rh18) potentially raises the concern
that the potency of the tested drugs will be underestimated. It is difficult to predict this,
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however, as the literature tends to agree on which genes are upregulated in fusion-positive
ARMS and engineered cells but not on the actual fold-change in expression of these genes.
Therefore, it will be necessary to work up the hits from the future drug screen in the
inducible PAX3-FOXO1 clonal cell line as well as in fusion-positive and -negative ARMS
cells.
The TaqMan assays also show that sustained expression of the fusion protein is
necessary to maintain these transcriptional changes, as the levels of these three genes are not
significantly different between the uninduced and induced states in the cells that lost PAX3FOXO1 expression after continuous culture for two months. Therefore, the utility of these
inducible cells in furthering the study of fusion-positive ARMS lies in the targeting of
synthetically lethal relationships that evolve early in the course of PAX3-FOXO1 expression.
Again, previous studies that used inducible systems also restricted their experiments to a
similar time course, allowing for comparability of results, but it should be noted that
constitutively expressing systems have revealed a greater number of upregulated genes than
their inducible counterparts (23). The number of hits from any future drug screen may thus
be limited by the relatively fewer synthetically lethal relationships at play.
From here, the uninduced and doxycycline-induced PAX3-FOXO1 clonal cells will
be tested against each other in a high-throughput chemical screen that primarily focuses on
inhibitors of DNA damage repair that are already in clinical use. Since the two cell
populations will differ only in their expression of PAX3-FOXO1, any inhibitor that
preferentially causes cell death in the induced cells can be assumed to target a DNA repair
mechanism that has become synthetically lethal as a direct result of the fusion protein and not
any number of the other genetic changes that have likely occurred in ARMS cells. These
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inhibitors will be selected for confirmatory screens; the trial clonigenic assay of U2OS cells
treated with etoposide provides a standard against which the experimental conditions for
further workup of hits can be adjusted.
Incidentally, it is interesting to note that while DAPK, FGFR4, MyoD, and initially
GREM1 were chosen as proxy genes based on a combination of the literature and
endogenous function, only FGFR4 and MyoD, as discussed above, have been studied closely
in the context of fusion-positive ARMS. The roles of DAPK and GREM1 have instead
primarily been investigated in the broader context of mechanisms common to multiple
cancers. While mechanistic studies of these genes are beyond the scope of this project, future
research may reveal additional insight into the “transcriptional reprogramming” that PAX3/7FOXO1 triggers.
What is known about DAPK is that it is active in apoptosis, autophagy, cell
migration, and inflammation. It has typically been classified as a tumor suppressor that is
downregulated secondary to increased methylation in many cancers (58). DAPK regulates
cell death as well as cytoskeletal rearrangements, and lower levels of this protein have been
correlated with increased metastasis (59). However, other studies have suggested that in
certain contexts, DAPK may actually be pro-oncogenic (58), which would be more consistent
with the RNA and cDNA data presented here and with the results of a number of previous
studies (23, 28, 31). Additionally, FOXA1, a transcription factor in the same family as
FOXO1, has been found to decrease the methylation status of DAPK in adenocarcinoma of
the breast (60). Most intriguingly, DAPK has been found to be synthetically lethal to ERnegative breast, pancreatic, and ovarian cancer cells with p53 mutations (61). Although p53
mutations are typically not linked to ARMS and instead are more closely associated with
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ERMS’ genetic picture (62), there may be potential for DAPK to be synthetically lethal in
ARMS secondary to mutations in or downregulation of other tumor suppressors.
Given its known endogenous functions, the role of GREM1 in the pathogenesis of
ARMS is not difficult to imagine. It is an antagonist of BMP signaling, which in turn
functions in embryonic and bone development (63); as discussed above, inhibition of
terminal development and differentiation of muscle tissue is one of the key functions of
PAX3/7-FOXO1. Independently of BMP signaling, GREM1 is a VEGF receptor-2 agonist
that may therefore play roles in tumor-related angiogenesis (64) and enhance metastatic
potential. The questions that surround DAPK’s and GREM1’s roles in fusion-positive ARMS
serve as symbolic reminders that the mechanisms of the hits from chemical screens may not
be well understood even when linked to a specific gene through follow-up or parallel siRNA
screens.
There is clearly still much to be studied about RMS, and particularly fusion-positive
ARMS, on multiple fronts. That ARMS disproportionately affects the pediatric population
and carries a poor prognosis, while clinically discouraging, means that there are many
potential life-years to be gained once this malignancy is better understood. This inducible
PAX3-FOXO1 clonal cell line and the future high-throughput drug screen address just one of
the challenges posed by this malignancy, but will hopefully open the door to not only
identifying new targeted therapies but investigating the molecular and genetic pathways by
which these therapies exert their specificity.
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